382 related articles for article (PubMed ID: 26394060)
1. Effects of Doxorubicin Delivery Systems and Mild Hyperthermia on Tissue Penetration in 3D Cell Culture Models of Ovarian Cancer Residual Disease.
Eetezadi S; De Souza R; Vythilingam M; Lessa Cataldi R; Allen C
Mol Pharm; 2015 Nov; 12(11):3973-85. PubMed ID: 26394060
[TBL] [Abstract][Full Text] [Related]
2. A novel two-step mild hyperthermia for advanced liposomal chemotherapy.
Li L; ten Hagen TL; Haeri A; Soullié T; Scholten C; Seynhaeve AL; Eggermont AM; Koning GA
J Control Release; 2014 Jan; 174():202-8. PubMed ID: 24269966
[TBL] [Abstract][Full Text] [Related]
3. The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles.
Kim TH; Mount CW; Gombotz WR; Pun SH
Biomaterials; 2010 Oct; 31(28):7386-97. PubMed ID: 20598741
[TBL] [Abstract][Full Text] [Related]
4. Enhanced transcellular penetration and drug delivery by crosslinked polymeric micelles into pancreatic multicellular tumor spheroids.
Lu H; Utama RH; Kitiyotsawat U; Babiuch K; Jiang Y; Stenzel MH
Biomater Sci; 2015 Jul; 3(7):1085-95. PubMed ID: 26221942
[TBL] [Abstract][Full Text] [Related]
5. Mixed micelles for encapsulation of doxorubicin with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines versus Doxil
Cagel M; Bernabeu E; Gonzalez L; Lagomarsino E; Zubillaga M; Moretton MA; Chiappetta DA
Biomed Pharmacother; 2017 Nov; 95():894-903. PubMed ID: 28903185
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
Peng ZH; Kopeček J
J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
[TBL] [Abstract][Full Text] [Related]
7. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.
Sun JJ; Chen YC; Huang YX; Zhao WC; Liu YH; Venkataramanan R; Lu BF; Li S
Acta Pharmacol Sin; 2017 Jun; 38(6):823-834. PubMed ID: 28504251
[TBL] [Abstract][Full Text] [Related]
8. Temperature-triggered on-demand drug release enabled by hydrogen-bonded multilayers of block copolymer micelles.
Zhu Z; Gao N; Wang H; Sukhishvili SA
J Control Release; 2013 Oct; 171(1):73-80. PubMed ID: 23831052
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
10. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy.
Li L; ten Hagen TL; Hossann M; Süss R; van Rhoon GC; Eggermont AM; Haemmerich D; Koning GA
J Control Release; 2013 Jun; 168(2):142-50. PubMed ID: 23524188
[TBL] [Abstract][Full Text] [Related]
11. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
[TBL] [Abstract][Full Text] [Related]
12. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin.
Tang N; Du G; Wang N; Liu C; Hang H; Liang W
J Natl Cancer Inst; 2007 Jul; 99(13):1004-15. PubMed ID: 17596572
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
14. Combined effects of laser-ICG photothermotherapy and doxorubicin chemotherapy on ovarian cancer cells.
Tang Y; McGoron AJ
J Photochem Photobiol B; 2009 Dec; 97(3):138-44. PubMed ID: 19811928
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin.
Xiong XB; Ma Z; Lai R; Lavasanifar A
Biomaterials; 2010 Feb; 31(4):757-68. PubMed ID: 19818492
[TBL] [Abstract][Full Text] [Related]
16. Polyethylene glycol modified ORMOSIL theranostic nanoparticles for triggered doxorubicin release and deep drug delivery into ovarian cancer spheroids.
Nagesetti A; Srinivasan S; McGoron AJ
J Photochem Photobiol B; 2017 Sep; 174():209-216. PubMed ID: 28800509
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
18. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
Füredi A; Szebényi K; Tóth S; Cserepes M; Hámori L; Nagy V; Karai E; Vajdovich P; Imre T; Szabó P; Szüts D; Tóvári J; Szakács G
J Control Release; 2017 Sep; 261():287-296. PubMed ID: 28700899
[TBL] [Abstract][Full Text] [Related]
19. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
20. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
